Clinic Roundup
• Entremed Inc., of Rockville, Md., said it started a Phase II study, titled “Phase II Study of Oral ENDM-2076 Administered to Patients with Ovarian Clear Cell Carcinomas.”
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.